Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Clark, W. F.    Related Articles in PubMed    PubMed Citation    PubMed

UPDATE

Therapeutic Plasma Exchange: An Update from the Canadian Apheresis Group

William F. Clark, MD; Gail A. Rock, PhD, MD; Noel Buskard, MD; Kenneth H. Shumak, MD; Pierre LeBlond, MD; David Anderson, MD; David M. Sutton, MD, for the Canadian Apheresis Group*

21 September 1999 | Volume 131 Issue 6 | Pages 453-462

In 1997, the Canadian Apheresis Group reviewed data on 103 416 plasma exchange procedures that had been collected since 1980. Although the number of plasma exchanges gradually increased (from 3189 to 8208 per year), the pattern changed. In 1981, the five most frequent indications for plasma exchange resulted in 55% of all such procedures; by 1997, the five most frequent indications for plasma exchange resulted in 81.1% of all such procedures. During this period, three conditions that were originally among the most frequent indications for plasma exchange became among the least frequent. This paper reviews the published evidence that supports or refutes the use of plasma exchange in the category of the five most frequent indications from 1981 to 1997: thrombotic thrombocytopenic purpura, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Waldenstrom macroglobulinemia, the Guillain-Barré syndrome, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. For most disorders, use of plasma exchange procedures is correlated with published evidence, and the changing patterns of plasma exchange use by members of the Canadian Apheresis Group reflect published evidence. Annual center-by-center reviews of use of plasma exchange may also have influenced practice patterns.

Author and Article Information

From London Health Sciences Centre, London, Ontario, Canada; Ottawa Hospital and Canadian Apheresis Group, Ottawa, Ontario, Canada; Vancouver Hospital and Health Centre, Vancouver, British Columbia, Canada; Toronto Sunnybrook Regional Cancer Centre and the Toronto Hospital, Toronto, Ontario, Canada; Hopital du St. Sacrement, Quebec, Quebec, Canada; Victoria General Hospital, Halifax, Nova Scotia, Canada.

For members of the Canadian Apheresis Group, see Appendix.

Requests for Reprints: William F. Clark, MD, Division of Nephrology, London Health Sciences Centre, Victoria Campus, 375 South Street, London, Ontario N6A 4G5, Canada.

Current Author Addresses: Dr. Clark: Division of Nephrology, London Health Sciences Centre, Victoria Campus, 375 South Street, London, Ontario N6A 4G5, Canada.

Dr. Rock: Ottawa Hospital and Canadian Apheresis Group, 270 Sandridge Road, Ottawa, Ontario K1L 5A2, Canada.

Dr. Buskard: Vancouver Hospital and Health Centre, 910 10th Avenue West, Vancouver, British Columbia V5Z 4E3, Canada.

Dr. Shumak: Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview, Toronto, Ontario M4N 3M5, Canada.

Dr. LeBlond: Hôpital du St. Sacrement, 1050 Chemin Ste-Foy, Quebec, Quebec G1S 4L8, Canada.

Dr. Anderson: Victoria General Hospital, MB132-1278 Tower Road, Halifax, Nova Scotia B3H 2Y9, Canada.

Dr. Sutton: The Toronto Hospital, 037-200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.

Related articles in Annals:

Letters
Therapeutic Plasma Exchange
Fadi Fakhouri, François Vincent, AND Christophe Legendre

Annals 2000 132: 760. [Full Text]  

Letters
Therapeutic Plasma Exchange
William F. Clark, Gail Rock, AND Kenneth A. Shumak

Annals 2000 132: 760-761. [Full Text]  

This article has been cited by other articles:

				A. X. Garg, T. Greene, and N. W. Levin A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance Nephrol. Dial. Transplant., January 1, 2008; 23(1): 52 - 55. [Full Text] [PDF]

				J. Caprioli, M. Noris, S. Brioschi, G. Pianetti, F. Castelletti, P. Bettinaglio, C. Mele, E. Bresin, L. Cassis, S. Gamba, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome Blood, August 15, 2006; 108(4): 1267 - 1279. [Abstract] [Full Text] [PDF]

				H. C. Lehmann, H.-P. Hartung, G. R. Hetzel, O. Stuve, and B. C. Kieseier Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol, July 1, 2006; 63(7): 930 - 935. [Abstract] [Full Text] [PDF]

				C Pagnoux, J-M Korach, and L Guillevin Indications for plasma exchange in systemic lupus erythematosus in 2005 Lupus, November 1, 2005; 14(11): 871 - 877. [Abstract] [PDF]

				M. Noris and G. Remuzzi Hemolytic Uremic Syndrome J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1035 - 1050. [Full Text] [PDF]

				M. L. Linenberger and T. H. Price Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications J Intensive Care Med, March 1, 2005; 20(2): 88 - 103. [Abstract] [PDF]

				W. F. Clark, A. X. Garg, P. G. Blake, G. A. Rock, A. P. Heidenheim, and D. L. Sackett Effect of Awareness of a Randomized Controlled Trial on Use of Experimental Therapy JAMA, September 10, 2003; 290(10): 1351 - 1355. [Abstract] [Full Text] [PDF]

				S. K. Vesely, J. N. George, B. Lammle, J.-D. Studt, L. Alberio, M. A. El-Harake, and G. E. Raskob ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood, July 1, 2003; 102(1): 60 - 68. [Abstract] [Full Text] [PDF]

				J. N. George and S. K. Vesely Thrombotic Thrombocytopenic Purpura: From the Bench to the Bedside, but Not Yet to the Community Ann Intern Med, January 21, 2003; 138(2): 152 - 153. [Full Text] [PDF]

				H. E. Gerritsen, R. Robles, B. Lammle, and M. Furlan Partial amino acid sequence of purified von Willebrand factor-cleaving protease Blood, September 15, 2001; 98(6): 1654 - 1661. [Abstract] [Full Text] [PDF]

				S. Imashuku, K. Kuriyama, T. Teramura, E. Ishii, N. Kinugawa, M. Kato, M. Sako, and S. Hibi Requirement for Etoposide in the Treatment of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis J. Clin. Oncol., May 15, 2001; 19(10): 2665 - 2673. [Abstract] [Full Text] [PDF]

				S. Schmaldienst, M. Mullner, A. Goldammer, S. Spitzauer, S. Banyai, W. H. Horl, and K. Derfler Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology, May 1, 2001; 40(5): 513 - 521. [Abstract] [Full Text] [PDF]

				J. N. George How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Blood, August 15, 2000; 96(4): 1223 - 1229. [Abstract] [Full Text] [PDF]

				F. Fakhouri, F. Vincent, and C. Legendre Therapeutic Plasma Exchange Ann Intern Med, May 2, 2000; 132(9): 760 - 760. [Full Text] [PDF]